{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024095","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.090805+00:00","generated_at":"2026-05-22T01:28:27.854393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA","bullets":["Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.","Operating expenses $16.0M (R&D $9.5M, G&A $6.5M) vs $13.2M in Q1 2024; net loss per share unchanged at $0.05.","OCU400 Phase 3 liMeliGhT RP trial recruiting; BLA/MAA filings targeted by mid-2026; ATMP classification from EMA.","OCU410ST Phase 2/3 pivotal trial for Stargardt disease to start mid-2025; BLA filing target 2027.","OCU410 for GA: Phase 2 dosing complete; 12-month data shows 4-line VA gain and 41% slower lesion growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024095","json":"https://secwatch.observer/filing/0001628280-25-024095.json","markdown":"https://secwatch.observer/filing/0001628280-25-024095.md","text":"https://secwatch.observer/filing/0001628280-25-024095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/0001628280-25-024095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:28:27.854393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}